Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Advanced Drainage Systems Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Advanced Drainage Systems Inc trades at $125.03 (market cap $9.44B). The key difference: Kymera Therapeutics Inc. Common Stock and Advanced Drainage Systems Inc are close in size by market cap, and Advanced Drainage Systems Inc pays a 0.64% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Advanced Drainage Systems Inc for 43 Days on average.
| KYMR | WMS | |
|---|---|---|
Market Cap | $8.88B | $9.44B |
Volume | 1,028,790 | 758,325 |
Sector | Health | Basic Materials |
52-Week High | $127.31 | $175.38 |
52-Week Low | $55.80 | $125.19 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $8.27B | $11.04B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WMS (Advanced Drainage Systems) trades at $126.73, up 0.64% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 EPS of $2.49, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news includes the release of its 2026 Sustainability Report and a quarterly dividend announcement. Institutional activity is mixed, with BlackRock acquiring a major stake while HighTower Advisors reduced its position.
The outlook for WMS is supported by earnings beats and structural growth in water management solutions, but near-term risks include a projected negative net cash flow for 2026 and competitive pressures. Analyst consensus is a Buy with a $188.20 price target, implying significant upside, though technical indicators suggest caution. Investment appeal hinges on execution of growth initiatives and margin stability amid economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
